Antidote: aspirin

Good old aspirin, therapeutic compound derived from willow bark, take a well-deserved bow. Well-publicized cases of aspirin induced bleeding are not the topic du jour.                                                                                   
We already knew that low- dose aspirin dramatically reduces the incidence of heart attacks and strokes. We also know that aspirin is the prototype anti-inflammatory. What about aspirin and cancer? Previous studies fueled the belief that aspirin and other non-steroidal anti-inflammatory drugs decreased the risk of breast and perhaps colon cancer. But there was also the concern that aspirin could cause bleeding unrelated to cancer.                                                                                                    
In fact, the opposite is true. A new German study of close to 1,000 patients, just published in the Journal of the American Medical Association, found that low-dose aspirin increases the sensitivity of stool testing for blood as a way of picking up advanced colon tumors. By causing these tumors to bleed, aspirin increases the likelihood that they will alert doctors for the need for a colonoscopy because of a positive stool test.                                                           
Meanwhile, in the UK, in multiple large trials involving 25,000 patients, a study in Lancet showed dramatic results. Patients taking aspirin for several years were 21% less likely to die of solid tumor cancers. The risk of death from colorectal cancer was 40% lower. The bottom line is that aspirin, though not without risks, appears to be helpful in both indirectly diagnosing and decreasing the risk of dying from cancer.
Aspirin, manufactured by Bayer since 1899, definitely has staying power.
Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.